Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 References  













Serazapine






●فارسی
  
Edit links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

Serazapine
Clinical data
Other namesCGS-15040A
Routes of
administration		By mouth
ATC code
  • None
Identifiers

  • methyl 2-methyl-1,3,4,16b-tetrahydro-2H,10H-benzo[5,6]pyrazino[2',1':3,4][1,4]diazepino[1,2-a]indole-16-carboxylate

CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H23N3O2
Molar mass361.445 g·mol−1
3D model (JSmol)

  • O=C(OC)C1=C2N(C3=C1C=CC=C3)CC4=CC=CC=C4N5C2CN(C)CC5

  • InChI=1S/C22H23N3O2/c1-23-11-12-24-17-9-5-3-7-15(17)13-25-18-10-6-4-8-16(18)20(22(26)27-2)21(25)19(24)14-23/h3-10,19H,11-14H2,1-2H3 checkY

  • Key:WPGUWABWNUSPMW-UHFFFAOYSA-N checkY

Serazapine (developmental code name CGS-15040A) is a serotonin 5-HT2 receptor antagonist that was investigated as a potential treatment for generalized anxiety disorder in the 1990s. In humans, serazapine was well tolerated at doses of 10 to 40 mg and was found to be superior to placebo for reducing anxiety symptoms as indicated by HAM-A scores.[1][2] However, clinical development was discontinued.[2]

References[edit]

  1. ^ Katz RJ, Landau PS, Lott M, Bystritsky A, Diamond B, Hoehn-Saric R, et al. (1 July 1993). "Serotonergic (5-HT2) mediation of anxiety-therapeutic effects of serazepine in generalized anxiety disorder". Biological Psychiatry. 34 (1–2): 41–4. doi:10.1016/0006-3223(93)90254-b. PMID 8104044. S2CID 24119589.
  • ^ a b "Serazepine". Adis Insight. Springer Nature Switzerland AG. Retrieved 8 April 2021.



    • Retrieved from "https://en.wikipedia.org/w/index.php?title=Serazapine&oldid=1158164228"
    Categories: 
    ●Drugs not assigned an ATC code
     ●5-HT2 antagonists
     ●Abandoned drugs
     ●Anxiolytics
     ●Heterocyclic compounds with 5 rings
     ●Nitrogen heterocycles
     ●Methyl esters
     Hidden categories: 
    ●Articles with short description
     ●Short description matches Wikidata
     ●Articles with changed EBI identifier
     ●Chemical pages without DrugBank identifier
     ●Articles without KEGG source
     ●Drugs with no legal status
     ●Articles containing unverified chemical infoboxes
      


    ●This page was last edited on 2 June 2023, at 09:48 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki